| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Maddi A et al. | Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells. | 2006 | Bone | pmid:16567138 |
| Kim HR et al. | Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). | 2006 | Rheumatology (Oxford) | pmid:16567356 |
| Aihara N et al. | Low-energy irradiation stimulates formation of osteoclast-like cells via RANK expression in vitro. | 2006 | Lasers Med Sci | pmid:16568210 |
| Wang L et al. | Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to 1,25-dihydroxy vitamin D3. | 2006 | Biomaterials | pmid:16569430 |
| Iguchi H et al. | Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. | 2006 | J. Bone Miner. Metab. | pmid:16369893 |
| Miller CS et al. | Salivary biomarkers of existing periodontal disease: a cross-sectional study. | 2006 | J Am Dent Assoc | pmid:16570465 |
| Hermann-Arnhof KM et al. | Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. | 2006 | Crit. Care Med. | pmid:16374159 |
| Mazziotti G et al. | Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. | 2006 | Eur. J. Endocrinol. | pmid:16498049 |
| Iwasaki Y et al. | Uremic toxin and bone metabolism. | 2006 | J. Bone Miner. Metab. | pmid:16502128 |
| Mandelin J et al. | Human osteoblasts produce cathepsin K. | 2006 | Bone | pmid:16337236 |
| Jono S et al. | Vascular calcification in chronic kidney disease. | 2006 | J. Bone Miner. Metab. | pmid:16502129 |
| Van Poznak C et al. | Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. | 2006 | J. Clin. Pathol. | pmid:16394281 |
| Liu D et al. | Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. | 2006 | Eur. J. Oral Sci. | pmid:16460340 |
| Hsu HC et al. | Tumor necrosis factor ligand-receptor superfamily and arthritis. | 2006 | Curr. Dir. Autoimmun. | pmid:16394654 |
| Cohen S | Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases. | 2006 | Arthritis Rheum. | pmid:16463406 |
| Nakamura M et al. | [Bone remodeling and mineral homeostasis]. | 2006 | Clin Calcium | pmid:16397350 |
| Holen I and Shipman CM | Role of osteoprotegerin (OPG) in cancer. | 2006 | Clin. Sci. | pmid:16464170 |
| Kim SW et al. | Effects of mushroom, Pleurotus eryngii, extracts on bone metabolism. | 2006 | Clin Nutr | pmid:16359759 |
| Kobayashi Y and Takahashi N | [The pathophysiology of osteoporosis/osteopenia in gene mutant mice]. | 2006 | Clin Calcium | pmid:16465035 |
| Padagas J et al. | The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. | 2006 | Calcif. Tissue Int. | pmid:16362459 |
| Bi Y et al. | Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts. | 2006 | Bone | pmid:16364709 |
| Middleton-Hardie C et al. | Deletion of aspartate 182 in OPG causes juvenile Paget's disease by impairing both protein secretion and binding to RANKL. | 2006 | J. Bone Miner. Res. | pmid:16491292 |
| Nishi H et al. | No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism. | 2006 | Clin. Nephrol. | pmid:16509469 |
| Garlet GP et al. | Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors. | 2006 | Oral Microbiol. Immunol. | pmid:16390336 |
| Wohlfahrt JC et al. | No association between selected candidate gene polymorphisms and severe chronic periodontitis. | 2006 | J. Periodontol. | pmid:16512757 |
| Magal I et al. | Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. | 2006 | Br. J. Haematol. | pmid:16512834 |
| Mehrotra M et al. | Fluid flow induces Rankl expression in primary murine calvarial osteoblasts. | 2006 | J. Cell. Biochem. | pmid:16514640 |
| Yamamoto T et al. | Cytokine production in human periodontal ligament cells stimulated with Porphyromonas gingivalis. | 2006 | J. Periodont. Res. | pmid:17076781 |
| Matsumoto K et al. | Cytokine profile in synovial fluid from patients with internal derangement of the temporomandibular joint: a preliminary study. | 2006 | Dentomaxillofac Radiol | pmid:17082335 |
| Zdzisińska B and Kandefer-Szerszeń M | [The role of RANK/RANKL and OPG in multiple myeloma]. | 2006 | Postepy Hig Med Dosw (Online) | pmid:17013366 |
| Ulivieri FM et al. | Increased osteoprotegerin in Italian haemodialysis patients. | 2006 | Osteoporos Int | pmid:17019516 |
| Soedarsono N et al. | Evaluation of RANK/RANKL/OPG gene polymorphisms in aggressive periodontitis. | 2006 | J. Periodont. Res. | pmid:16953816 |
| Bargnoux AS et al. | Renal transplantation decreases osteoprotegerin levels. | 2006 | Transplant. Proc. | pmid:16980077 |
| Kobayashi-Sakamoto M et al. | Osteoprotegerin protects endothelial cells against apoptotic cell death induced by Porphyromonas gingivalis cysteine proteinases. | 2006 | FEMS Microbiol. Lett. | pmid:16981905 |
| Grzegorzewska AE and Mlot-Michalska M | Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone. | 2006 | Adv Perit Dial | pmid:16983970 |
| Ge WL et al. | [Expression of c-fos, OPG, OPGL in rabbit mandibular distraction osteogenesis zone]. | 2006 | Zhejiang Da Xue Xue Bao Yi Xue Ban | pmid:17063541 |
| Martini G et al. | The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma. | 2006 | Haematologica | pmid:17145616 |
| Hsu YH et al. | Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. | 2006 | Hum. Genet. | pmid:16249885 |
| Pan G et al. | Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. | 2006 | AIDS Res. Hum. Retroviruses | pmid:17147500 |
| Palmqvist P et al. | Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. | 2006 | J. Biol. Chem. | pmid:16251181 |
| Cross SS et al. | Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? | 2006 | Int. J. Cancer | pmid:16287088 |
| Pearse RN | Wnt antagonism in multiple myeloma: a potential cause of uncoupled bone remodeling. | 2006 | Clin. Cancer Res. | pmid:17062713 |
| Evans CE et al. | Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK. | 2006 | BMC Musculoskelet Disord | pmid:16519799 |
| McClung MR | Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. | 2006 | Curr Osteoporos Rep | pmid:16527005 |
| Hesry V et al. | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. | 2006 | Prostate | pmid:16541419 |
| Humphrey EL et al. | Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. | 2006 | Bone | pmid:16298558 |
| Sandra F et al. | Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. | 2006 | Oral Oncol. | pmid:16413220 |
| Evans BA et al. | Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. | 2006 | J. Bone Miner. Res. | pmid:16418778 |
| Berry JE et al. | JunB as a downstream mediator of PTHrP actions in cementoblasts. | 2006 | J. Bone Miner. Res. | pmid:16418780 |
| Yang M et al. | Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. | 2006 | Blood | pmid:16304045 |
| Fan X et al. | Response to mechanical strain in an immortalized pre-osteoblast cell is dependent on ERK1/2. | 2006 | J. Cell. Physiol. | pmid:16419041 |
| Sylvester FA et al. | Are activated T cells regulators of bone metabolism in children with Crohn disease? | 2006 | J. Pediatr. | pmid:16647405 |
| Bersinger NA et al. | PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis. | 2006 | Am. J. Obstet. Gynecol. | pmid:16635455 |
| Morena M et al. | Plasma osteoprotegerin is associated with mortality in hemodialysis patients. | 2006 | J. Am. Soc. Nephrol. | pmid:16280472 |
| Walsh MC et al. | Osteoimmunology: interplay between the immune system and bone metabolism. | 2006 | Annu. Rev. Immunol. | pmid:16551243 |
| Wakita T et al. | Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. | 2006 | J. Dent. Res. | pmid:16798863 |
| Shin JY et al. | Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. | 2006 | Diabetes Care | pmid:16801598 |
| Xiang GD et al. | The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. | 2006 | Diabetes | pmid:16804084 |
| Galli C et al. | Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts. | 2006 | J. Periodontol. | pmid:16805686 |
| Holding CA et al. | The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. | 2006 | Biomaterials | pmid:16806459 |
| Chen G et al. | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. | 2006 | Cancer | pmid:16752412 |
| Samadfam R et al. | Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. | 2006 | J. Rheumatol. | pmid:16755666 |
| Kazama JJ et al. | Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. | 2006 | Ther Apher Dial | pmid:16817791 |
| Granchi D et al. | Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. | 2006 | J Bone Joint Surg Am | pmid:16818976 |
| Lee KS et al. | An antioxidant modulates expression of receptor activator of NF-kappaB in asthma. | 2006 | Exp. Mol. Med. | pmid:16819280 |
| Hjertner Ø et al. | Bone disease in multiple myeloma. | 2006 | Med. Oncol. | pmid:17303901 |
| Schenk-Braat EA and Bangma CH | [The search for better markers for prostate cancer than prostate-specific antigen]. | 2006 | Ned Tijdschr Geneeskd | pmid:16821452 |
| Deschner J et al. | Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. | 2006 | J Biomech | pmid:16038916 |
| Fiore CE et al. | Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. | 2006 | Horm. Metab. Res. | pmid:16823725 |
| Gajewska J et al. | Osteoprotegerin and C-telopeptide of type I collagen in Polish healthy children and adolescents. | 2006 | Adv Med Sci | pmid:17357324 |
| Shin HH et al. | Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells. | 2006 | Bone | pmid:16750437 |
| Zauli G and Secchiero P | The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. | 2006 | Cytokine Growth Factor Rev. | pmid:16750931 |
| Tat SK et al. | OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. | 2006 | Bone | pmid:16750945 |
| Sasaki N and Kusano E | [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG]. | 2006 | Clin Calcium | pmid:16751691 |
| Gannagé-Yared MH et al. | Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712667 |
| Rhee EJ et al. | The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712673 |
| Tannehill-Gregg SH et al. | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. | 2006 | Clin. Exp. Metastasis | pmid:16715352 |
| Chaki O | [Osteoporosis]. | 2006 | Nippon Rinsho | pmid:16689336 |
| Hess U | [The plasma cell myeloma--molecular pathogenesis and target therapies]. | 2006 | Ther Umsch | pmid:16689452 |
| Burton A | Regulation of RANKL might reduce bone metastases . | 2006 | Lancet Oncol. | pmid:16696160 |
| Wang Q et al. | [Effects of soybean isoflavones on expression levels of osteoprotegerin and osteoprotegerin ligand mRNAs in bone tissues of ovariectomized rats]. | 2006 | Zhong Xi Yi Jie He Xue Bao | pmid:16696921 |
| Liu YH et al. | [Effects of kangfengshi granules on expressions of osteoprotegerin, RANKL and M-CSF in bone tissues of rats with collagen-induced arthritis]. | 2006 | Zhong Xi Yi Jie He Xue Bao | pmid:16696922 |
| Raustyte G et al. | Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media. | 2006 | Int. J. Pediatr. Otorhinolaryngol. | pmid:16159670 |
| Yang YQ et al. | Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. | 2006 | Front. Biosci. | pmid:16146769 |
| Maruyama K et al. | Murine osteoblasts respond to LPS and IFN-gamma similarly to macrophages. | 2006 | J. Bone Miner. Metab. | pmid:17072737 |
| Kastritis E et al. | Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. | 2006 | Clin Lymphoma Myeloma | pmid:16879774 |
| Franklin M et al. | Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. | 2006 | Bone | pmid:16890505 |
| Stankovic KM and McKenna MJ | Current research in otosclerosis. | 2006 | Curr Opin Otolaryngol Head Neck Surg | pmid:16974150 |
| Kim CH et al. | Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. | 2006 | Bone | pmid:16860618 |
| Nemoto E et al. | Regulation of cementoblast function by P. gingivalis lipopolysaccharide via TLR2. | 2006 | J. Dent. Res. | pmid:16861291 |
| Jia L and Jin TY | Combined effect of fluoride and arsenate on gene expression of osteoclast differentiation factor and osteoprotegerin. | 2006 | Biomed. Environ. Sci. | pmid:17190191 |
| Yamaguchi M et al. | RANKL increase in compressed periodontal ligament cells from root resorption. | 2006 | J. Dent. Res. | pmid:16861294 |
| Grzegorzewska AE and MÅ‚ot M | Serum markers of bone turnover in dialyzed patients separated according to age. | 2006 | Int Urol Nephrol | pmid:16868703 |
| Robertson KM et al. | Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. | 2006 | J. Bone Miner. Res. | pmid:16869726 |
| Kiechl S et al. | The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. | 2006 | Expert Rev Cardiovasc Ther | pmid:17173497 |
| Baek KH et al. | Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. | 2006 | Bone | pmid:16905375 |
| Bernstein CN | Inflammatory bowel diseases as secondary causes of osteoporosis. | 2006 | Curr Osteoporos Rep | pmid:16908001 |
| Baldock PA et al. | Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. | 2006 | J. Bone Miner. Res. | pmid:16995817 |
| D'Amore M et al. | Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women. | 2006 | Panminerva Med | pmid:17215793 |
| Luo XH et al. | Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. | 2006 | J. Bone Miner. Res. | pmid:16995820 |